Uncategorized

Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes

Published

4 weeks ago

on

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version